Wires·
Standing by — next sweep in ~14 min.
Markets
Dow+0.79%Russell 2000-0.45%Nasdaq+2.38%S&P 500+1.59%VXX-4.29%IEF+0.02%GLD-1.34%SLV-1.12%USO+1.35%UUP-0.28%Dow+0.79%Russell 2000-0.45%Nasdaq+2.38%S&P 500+1.59%VXX-4.29%IEF+0.02%GLD-1.34%SLV-1.12%USO+1.35%UUP-0.28%

MDT

Medtronic PlcHealth Careinsider_universe
Last close $81.63Jun 28, 2026
Day +0.80%

Currently held

  • Agent 5 — Dip Buyer (Evolving)long
    18 sh @ $76.30 · stop $71.13
    +$82.53 unrealized
  • Agent 20 — SIR Price/Volumelong
    21 sh @ $81.93 · stop $75.38
    -$21.95 unrealized

Everything we've seen

  1. ·Jun 29, 3:34 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  2. ·Jun 29, 3:34 PMstreamnews

    Medtronic plc (MDT) CEO Discloses the Impacts of Tariffs on the Company

    Medtronic plc (NYSE:MDT) is one of the 10 Best Brain-Computer Interface Stocks to Buy. On June 8, Medtronic plc (NYSE:MDT) Chairman and CEO Geoffrey Martha said on Fox Business Network’s The Claman Countdown that the company now expects a $250 million tariff hit for fiscal 2027, down from a prior $300 million estimate due to supply chain […]

  3. ·Jun 29, 3:34 PMstreamnews

    Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July

    Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.

  4. ·Jun 29, 3:34 PMstreamnews

    3 Stocks I'm Not Selling No Matter What the Market Does

    I focus on well-run companies that pay reliable dividends; a bull or bear market doesn't change how well a company is run.

  5. ·Jun 29, 3:34 PMstreamnews

    Medtronic: Coming Back, But Not Yet Ready For Greatness

    Medtronic's asset quality is high, but strategic diffusion and slow growth hinder valuation. Click here to read why MDT stock is a Hold.

  6. ·Jun 29, 3:34 PMstreamnews

    Here is Why Medtronic (MDT) is One of the Best Long Term Stocks to Buy According to Hedge Funds

    Medtronic (NYSE:MDT) is one of the best long term stocks to buy according to hedge funds. On June 8, Medtronic received FDA 510(k) clearance for its Nellcor pulse oximetry system featuring the new Nell-EQ intelligent processor. This technology is engineered to provide more consistent and reliable pulse rate and oxygen saturation monitoring across various patient […]

  7. ·Jun 29, 3:34 PMstreamnews

    Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

    Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst ratings for high-yielding stocks, including accuracy rates.

  8. ·Jun 29, 3:34 PMstreamnews

    DRAM: Stealth Rallies And The Plenum Of Memory

    Roundhill Memory ETF (DRAM) targets DRAM/NAND/HBM leaders like SK Hynix, Samsung & Micron; July 10 SKHY listing may boost momentum—learn more.

  9. ·Jun 29, 3:19 PMstreamnews

    Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July

    Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.

  10. ·Jun 29, 3:19 PMstreamnews

    3 Stocks I'm Not Selling No Matter What the Market Does

    I focus on well-run companies that pay reliable dividends; a bull or bear market doesn't change how well a company is run.

  11. ·Jun 29, 3:19 PMstreamnews

    Medtronic: Coming Back, But Not Yet Ready For Greatness

    Medtronic's asset quality is high, but strategic diffusion and slow growth hinder valuation. Click here to read why MDT stock is a Hold.

  12. ·Jun 29, 3:19 PMstreamnews

    Here is Why Medtronic (MDT) is One of the Best Long Term Stocks to Buy According to Hedge Funds

    Medtronic (NYSE:MDT) is one of the best long term stocks to buy according to hedge funds. On June 8, Medtronic received FDA 510(k) clearance for its Nellcor pulse oximetry system featuring the new Nell-EQ intelligent processor. This technology is engineered to provide more consistent and reliable pulse rate and oxygen saturation monitoring across various patient […]

  13. ·Jun 29, 3:19 PMstreamnews

    Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

    Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst ratings for high-yielding stocks, including accuracy rates.

  14. ·Jun 29, 3:19 PMstreamnews

    DRAM: Stealth Rallies And The Plenum Of Memory

    Roundhill Memory ETF (DRAM) targets DRAM/NAND/HBM leaders like SK Hynix, Samsung & Micron; July 10 SKHY listing may boost momentum—learn more.

  15. ·Jun 29, 3:19 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  16. ·Jun 29, 3:19 PMstreamnews

    Medtronic plc (MDT) CEO Discloses the Impacts of Tariffs on the Company

    Medtronic plc (NYSE:MDT) is one of the 10 Best Brain-Computer Interface Stocks to Buy. On June 8, Medtronic plc (NYSE:MDT) Chairman and CEO Geoffrey Martha said on Fox Business Network’s The Claman Countdown that the company now expects a $250 million tariff hit for fiscal 2027, down from a prior $300 million estimate due to supply chain […]

  17. ·Jun 29, 3:04 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  18. ·Jun 29, 3:04 PMstreamnews

    Medtronic plc (MDT) CEO Discloses the Impacts of Tariffs on the Company

    Medtronic plc (NYSE:MDT) is one of the 10 Best Brain-Computer Interface Stocks to Buy. On June 8, Medtronic plc (NYSE:MDT) Chairman and CEO Geoffrey Martha said on Fox Business Network’s The Claman Countdown that the company now expects a $250 million tariff hit for fiscal 2027, down from a prior $300 million estimate due to supply chain […]

  19. ·Jun 29, 3:04 PMstreamnews

    Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July

    Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.

  20. ·Jun 29, 3:04 PMstreamnews

    3 Stocks I'm Not Selling No Matter What the Market Does

    I focus on well-run companies that pay reliable dividends; a bull or bear market doesn't change how well a company is run.

  21. ·Jun 29, 3:04 PMstreamnews

    Medtronic: Coming Back, But Not Yet Ready For Greatness

    Medtronic's asset quality is high, but strategic diffusion and slow growth hinder valuation. Click here to read why MDT stock is a Hold.

  22. ·Jun 29, 3:04 PMstreamnews

    Here is Why Medtronic (MDT) is One of the Best Long Term Stocks to Buy According to Hedge Funds

    Medtronic (NYSE:MDT) is one of the best long term stocks to buy according to hedge funds. On June 8, Medtronic received FDA 510(k) clearance for its Nellcor pulse oximetry system featuring the new Nell-EQ intelligent processor. This technology is engineered to provide more consistent and reliable pulse rate and oxygen saturation monitoring across various patient […]

  23. ·Jun 29, 3:04 PMstreamnews

    Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

    Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst ratings for high-yielding stocks, including accuracy rates.

  24. ·Jun 29, 3:04 PMstreamnews

    DRAM: Stealth Rallies And The Plenum Of Memory

    Roundhill Memory ETF (DRAM) targets DRAM/NAND/HBM leaders like SK Hynix, Samsung & Micron; July 10 SKHY listing may boost momentum—learn more.

  25. ·Jun 29, 2:48 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  26. ·Jun 29, 2:48 PMstreamnews

    Medtronic plc (MDT) CEO Discloses the Impacts of Tariffs on the Company

    Medtronic plc (NYSE:MDT) is one of the 10 Best Brain-Computer Interface Stocks to Buy. On June 8, Medtronic plc (NYSE:MDT) Chairman and CEO Geoffrey Martha said on Fox Business Network’s The Claman Countdown that the company now expects a $250 million tariff hit for fiscal 2027, down from a prior $300 million estimate due to supply chain […]

  27. ·Jun 29, 2:48 PMstreamnews

    Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July

    Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.

  28. ·Jun 29, 2:48 PMstreamnews

    3 Stocks I'm Not Selling No Matter What the Market Does

    I focus on well-run companies that pay reliable dividends; a bull or bear market doesn't change how well a company is run.

  29. ·Jun 29, 2:48 PMstreamnews

    Medtronic: Coming Back, But Not Yet Ready For Greatness

    Medtronic's asset quality is high, but strategic diffusion and slow growth hinder valuation. Click here to read why MDT stock is a Hold.

  30. ·Jun 29, 2:48 PMstreamnews

    Here is Why Medtronic (MDT) is One of the Best Long Term Stocks to Buy According to Hedge Funds

    Medtronic (NYSE:MDT) is one of the best long term stocks to buy according to hedge funds. On June 8, Medtronic received FDA 510(k) clearance for its Nellcor pulse oximetry system featuring the new Nell-EQ intelligent processor. This technology is engineered to provide more consistent and reliable pulse rate and oxygen saturation monitoring across various patient […]

  31. ·Jun 29, 2:48 PMstreamnews

    Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

    Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst ratings for high-yielding stocks, including accuracy rates.

  32. ·Jun 29, 2:33 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  33. ·Jun 29, 2:33 PMstreamnews

    Medtronic plc (MDT) CEO Discloses the Impacts of Tariffs on the Company

    Medtronic plc (NYSE:MDT) is one of the 10 Best Brain-Computer Interface Stocks to Buy. On June 8, Medtronic plc (NYSE:MDT) Chairman and CEO Geoffrey Martha said on Fox Business Network’s The Claman Countdown that the company now expects a $250 million tariff hit for fiscal 2027, down from a prior $300 million estimate due to supply chain […]

  34. ·Jun 29, 2:33 PMstreamnews

    Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July

    Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.

  35. ·Jun 29, 2:33 PMstreamnews

    3 Stocks I'm Not Selling No Matter What the Market Does

    I focus on well-run companies that pay reliable dividends; a bull or bear market doesn't change how well a company is run.

  36. ·Jun 29, 2:33 PMstreamnews

    Medtronic: Coming Back, But Not Yet Ready For Greatness

    Medtronic's asset quality is high, but strategic diffusion and slow growth hinder valuation. Click here to read why MDT stock is a Hold.

  37. ·Jun 29, 2:33 PMstreamnews

    Here is Why Medtronic (MDT) is One of the Best Long Term Stocks to Buy According to Hedge Funds

    Medtronic (NYSE:MDT) is one of the best long term stocks to buy according to hedge funds. On June 8, Medtronic received FDA 510(k) clearance for its Nellcor pulse oximetry system featuring the new Nell-EQ intelligent processor. This technology is engineered to provide more consistent and reliable pulse rate and oxygen saturation monitoring across various patient […]

  38. ·Jun 29, 2:33 PMstreamnews

    Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

    Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst ratings for high-yielding stocks, including accuracy rates.

  39. ·Jun 29, 2:18 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  40. ·Jun 29, 2:18 PMstreamnews

    Medtronic plc (MDT) CEO Discloses the Impacts of Tariffs on the Company

    Medtronic plc (NYSE:MDT) is one of the 10 Best Brain-Computer Interface Stocks to Buy. On June 8, Medtronic plc (NYSE:MDT) Chairman and CEO Geoffrey Martha said on Fox Business Network’s The Claman Countdown that the company now expects a $250 million tariff hit for fiscal 2027, down from a prior $300 million estimate due to supply chain […]

  41. ·Jun 29, 2:18 PMstreamnews

    Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July

    Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.

  42. ·Jun 29, 2:18 PMstreamnews

    3 Stocks I'm Not Selling No Matter What the Market Does

    I focus on well-run companies that pay reliable dividends; a bull or bear market doesn't change how well a company is run.

  43. ·Jun 29, 2:18 PMstreamnews

    Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic

    Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.

  44. ·Jun 29, 2:03 PMstreamnews

    3 Stocks I'm Not Selling No Matter What the Market Does

    I focus on well-run companies that pay reliable dividends; a bull or bear market doesn't change how well a company is run.

  45. ❖Jun 29, 9:20 AMnewsvia finnhub

    How Abbott's Largest Segment Is Preparing for the Next Growth Phase

    ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.

  46. ❖Jun 29, 7:16 AMnewsvia finnhub

    Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic

    Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.

  47. ❖Jun 29, 5:19 AMnewsvia finnhub

    DRAM: Stealth Rallies And The Plenum Of Memory

    Roundhill Memory ETF (DRAM) targets DRAM/NAND/HBM leaders like SK Hynix, Samsung & Micron; July 10 SKHY listing may boost momentum—learn more.

  48. ❖Jun 29, 3:46 AMnewsvia finnhub

    Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

    Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst ratings for high-yielding stocks, including accuracy rates.

  49. ❖Jun 29, 1:30 AMnewsvia finnhub

    Here is Why Medtronic (MDT) is One of the Best Long Term Stocks to Buy According to Hedge Funds

    Medtronic (NYSE:MDT) is one of the best long term stocks to buy according to hedge funds. On June 8, Medtronic received FDA 510(k) clearance for its Nellcor pulse oximetry system featuring the new Nell-EQ intelligent processor. This technology is engineered to provide more consistent and reliable pulse rate and oxygen saturation monitoring across various patient […]

  50. ❖Jun 28, 4:55 PMnewsvia finnhub

    Medtronic: Coming Back, But Not Yet Ready For Greatness

    Medtronic's asset quality is high, but strategic diffusion and slow growth hinder valuation. Click here to read why MDT stock is a Hold.

  51. ❖Jun 27, 6:35 PMnewsvia finnhub

    3 Stocks I'm Not Selling No Matter What the Market Does

    I focus on well-run companies that pay reliable dividends; a bull or bear market doesn't change how well a company is run.

  52. ❖Jun 27, 5:05 PMnewsvia finnhub

    Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July

    Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.

  53. ❖Jun 27, 11:32 AMnewsvia finnhub

    Medtronic plc (MDT) CEO Discloses the Impacts of Tariffs on the Company

    Medtronic plc (NYSE:MDT) is one of the 10 Best Brain-Computer Interface Stocks to Buy. On June 8, Medtronic plc (NYSE:MDT) Chairman and CEO Geoffrey Martha said on Fox Business Network’s The Claman Countdown that the company now expects a $250 million tariff hit for fiscal 2027, down from a prior $300 million estimate due to supply chain […]

  54. ❖Jun 27, 2:28 AMnewsvia finnhub

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  55. ❖Jun 26, 6:06 AMnewsvia finnhub

    How Investors May Respond To Medtronic (MDT) Optimism On Renal Denervation Amid Mixed Quantitative Signals

    In June 2026, Medtronic drew attention as analysts emphasized its positioning in cardiac ablation, diabetes care and hypertension treatment, alongside progress in its FDA-approved Symplicity Spyral renal denervation system. An intriguing angle is that these supportive views emerged even as some quantitative ratings turned cautious, underscoring differing interpretations of Medtronic’s near-term earnings outlook. With Medtronic shares recently posting a modest gain, we’ll examine how...

  56. ❖Jun 25, 10:40 PMnewsvia finnhub

    Tag along with Jason at CISCE: How is global health care linking up in China?

    This is a report from China.org.cn

  57. ❖Jun 25, 4:03 PMnewsvia finnhub

    Cerebras Stock Offers a Clear Warning that Highly Anticipated IPOs from OpenAI and Anthropic Could Crash Back to Earth Fast

    IPOs are the new meme stocks, surging to record highs before crashing below their debut prices in a matter of days.

  58. ❖Jun 25, 2:20 PMnewsvia finnhub

    Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy

    Abbott Laboratories (NYSE:ABT) at $90.53 is a Buy. The healthcare giant has been swept up in a sector-wide rotation out of defensive names, even as its diabetes franchise compounds and its medical devices unit posts double-digit growth. Abbott spans medical devices, diagnostics, established pharmaceuticals, and nutrition, with Robert B. Ford as CEO. FreeStyle Libre, the ... Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Bu

  59. ❖Jun 25, 11:05 AMnewsvia finnhub

    Former Medtronic CEO Bill Hawkins Joins Ketryx Board to Solve the AI Bottleneck in Life Sciences

    Cambridge, Massachusetts--(Newsfile Corp. - June 25, 2026) - Ketryx, the agentic continuous compliance platform for safety-critical product development, announced today that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Ketryx announces that William A. Hawkins, former Chairman and CEO of Medtronic, joins its Board of...

  60. ❖Jun 25, 9:18 AMnewsvia finnhub

    Boston Scientific's Fall From Penthouse To Doghouse Creates A Value Opportunity

    Boston Scientific has suffered a 50% share price decline amid decelerating growth, but fundamentals-based valuation now appears attractive. Read more here.

  61. ❖Jun 25, 2:22 AMnewsvia finnhub

    Needham Remains Bullish On Medtronic (MDT) Amid Renal Device Growth

    With 60 hedge funds holding bullish positions and analysts seeing 19.84% upside potential, Medtronic plc (NYSE:MDT) ranks among the top stocks to buy for financial stability. Medtronic plc (NYSE:MDT) drew attention last week from both a direct analyst update on its renal denervation business and a broader policy shift in the structural heart space. On […]

  62. ?Jun 24, 9:45 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is up 1.77% today, a modest but real move suggesting genuine buying flow. The headline (CardioMech appointing a new chairman) is tangentially related to the medtech/cardiac space but not a direct MDT catalyst, so it doesn't explain or amplify the move. Macro context shows T10YIE at 2.0σ below trend — lower inflation expectations are mildly supportive for long-duration sensitive sectors including healthcare/medtech, as it reduces discount rate pressure on future cash flows. With 360 minutes remaining (essentially the full session still ahead), there is ample time for continuation. No reversal signal or fade pattern is evident from the data provided. The absence of a strong specific catalyst keeps conviction moderate — this reads as broad sector/macro-driven buying rather than a high-conviction news-driven rip. Volume and intraday pattern data are unavailable, preventing a stronger read. Overall, slight lean toward continuation given supportive macro backdrop, time remaining, and no contrary evidence, but probability stays conservative given the limited catalyst clarity.

  63. !Jun 24, 9:45 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    MDT is up 1.77% today, a modest but real move suggesting genuine buying flow. The headline (CardioMech appointing a new chairman) is tangentially related to the medtech/cardiac space but not a direct MDT catalyst, so it doesn't explain or amplify the move. Macro context shows T10YIE at 2.0σ below trend — lower inflation expectations are mildly supportive for long-duration sensitive sectors including healthcare/medtech, as it reduces discount rate pressure on future cash flows. With 360 minutes remaining (essentially the full session still ahead), there is ample time for continuation. No reversal signal or fade pattern is evident from the data provided. The absence of a strong specific catalyst keeps conviction moderate — this reads as broad sector/macro-driven buying rather than a high-conviction news-driven rip. Volume and intraday pattern data are unavailable, preventing a stronger read. Overall, slight lean toward continuation given supportive macro backdrop, time remaining, and no contrary evidence, but probability stays conservative given the limited catalyst clarity.

  64. ❖Jun 24, 9:30 AMnewsvia finnhub

    [Latest] Global Neonatal Intensive Care Respiratory Devices Market Size/Share Worth USD 5.7 Billion by 2035 at a 10.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)

    [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Neonatal Intensive Care Respiratory Devices Market size & share revenue was valued at approximately USD 2.1 Billion in 2025 and is expected to reach USD 2.3 Billion in 2026 and is expected to reach around USD 5.7 Billion by 2035, at a CAGR of 10.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Inspirat

  65. ❖Jun 24, 6:01 AMnewsvia finnhub

    CardioMech Shareholders Appoint Ramin Mousavi as Chairman of the Board

    Norway-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology in Fridley, MN, today announced the appointment of Ramin Mousavi as Chairman of the Board, effective immediately.

  66. ❖Jun 24, 6:00 AMnewsvia finnhub

    MiniMed launches Abbott-made Instinct glucose sensor in Europe

    Overseas markets are central to MiniMed’s business, accounting for 70% of reported net sales in the company’s 2026 financial year.

  67. ❖Jun 23, 4:50 PMnewsvia finnhub

    2 High-Yield Dividend Stocks to Buy and Hold for a Decade

    Don't wait until they recover to initiate positions.

  68. ❖Jun 23, 2:11 PMnewsvia finnhub

    The Cash-Flow Fortress The Stryker Stock Bears Keep Missing

    While the market fixates on a disruptive quarter for Stryker stock, the company's powerful ability to convert profit into hard cash reveals a deeper, under-appreciated resilience.

  69. ❖Jun 23, 10:41 AMnewsvia finnhub

    Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own”

    Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down. A caller asked about Cramer’s thoughts on the stock, and he replied: Now, I gotta tell you something, I was shocked at the decline […]

  70. ❖Jun 23, 10:31 AMnewsvia finnhub

    Jim Cramer on Intuitive Surgical: “Too Much Competition”

    Intuitive Surgical, Inc. (NASDAQ:ISRG) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down. Inquiring about the stock, a caller asked if it is a buy. Cramer replied: Too much competition, too much competition… Used to be king, […]

  71. ❖Jun 23, 10:13 AMnewsvia finnhub

    Is Procedure Growth Broad-Based Enough to Support ISRG's 2026 Outlook?

    ISRG raises its 2026 outlook after strong Q1 results, but can broad-based procedure growth offset emerging headwinds in key U.S. and global markets?

  72. ❖Jun 23, 9:12 AMnewsvia finnhub

    Medtronic (MDT) Just Closed Its $550 Million Scientia Vascular Deal

    Medtronic (NYSE:MDT) has completed its $550 million acquisition of Scientia Vascular. The deal brings specialized guidewires and catheters for cerebral vasculature into Medtronic's neurovascular portfolio. Management expects the transaction to be initially minimally dilutive to earnings and to turn accretive in later fiscal years. For investors tracking Medtronic, the Scientia Vascular deal adds another piece to the company’s neurovascular therapy ambitions at a time when the stock trades...

  73. ❖Jun 23, 7:39 AMnewsvia finnhub

    Medtronic appoints veteran J&J exec as first CFO of innovation

    Eric Lenard comes to the new position with more than two decades of experience in medtech finance, as Medtronic steps up its investment in innovation.

  74. ❖Jun 23, 7:13 AMnewsvia finnhub

    Medtronic (MDT) Stock After Recent Slide: What Do Current Valuation Models Suggest?

    If you are wondering whether Medtronic stock is offering good value at its recent price, this article focuses squarely on what the current share price implies about the company. Medtronic recently closed at US$79.27, with the share price roughly flat over the past month, edging up 0.9%, while year to date it has fallen 17.5% and is down 4.9% over the past year. Recent coverage of Medtronic has centered on its position in medical devices and how investors are weighing long term demand for its...

  75. ❖Jun 22, 10:28 AMnewsvia finnhub

    Here's How Macro Trends and Currency Headwind Restrict GMED's Growth

    Globus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.

  76. ❖Jun 22, 9:30 AMnewsvia finnhub

    Is It Worth Investing in Medtronic (MDT) Based on Wall Street's Bullish Views?

    Based on the average brokerage recommendation (ABR), Medtronic (MDT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

  77. ❖Jun 21, 6:53 AMnewsvia finnhub

    Medtronic (MDT) Completes $550M Acquisition of Scientia Vascular

    Medtronic (NYSE:MDT) is one of the most undervalued NYSE stocks to invest in. On June 12, Medtronic officially completed its acquisition of Scientia Vascular, a Salt Lake City-based medical device firm, in a transaction valued at $550 million. The deal includes potential post-acquisition earn-outs and milestone payments, and it marks a significant move for Medtronic […]

  78. ❖Jun 19, 9:43 AMnewsvia finnhub

    The Nasdaq 100 Has Tripled Since 2020, But These 10 Mega-Caps Are Still Underwater

    The Nasdaq 100 has tripled since 2020, but 10 mega-caps still trade below pre-Covid levels. Who's still underwater and why?

  79. ❖Jun 18, 4:30 PMnewsvia finnhub

    Global ECG Patch and Holter Monitor Market Size/Share Worth USD 3.92 Billion by 2035 at a 9.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

    [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global ECG Patch and Holter Monitor Market size & share revenue was valued at approximately USD 1.87 Billion in 2025 and is expected to reach USD 2.04 Billion in 2026 and is expected to reach around USD 3.92 Billion by 2035, at a CAGR of 9.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are iRhythm Technologies

  80. ❖Jun 18, 4:20 PMnewsvia finnhub

    Dividend Champion, Contender, And Challenger Highlights: Week Of June 21

    Track weekly dividend updates for Champions, Contenders & Challengers: dividend changes, upcoming ex-dividend dates, and pay dates.

  81. ❖Jun 18, 3:30 PMnewsvia finnhub

    Lightning Round: It's time to buy SoFi, says Jim Cramer

    'Mad Money' host Jim Cramer weighs in on stocks including: SoFi, Rivian, Tractor Supply, Datadog, Boston Scientific, and more.

  82. ❖Jun 18, 7:01 AMnewsvia finnhub

    This Undervalued Medical-Devices Stock Is Poised for a Rebound

    Medtronic is deeply undervalued and a good bet for your portfolio. At the time, an uncertain growth outlook kept us from recommending the stock. Four months later, it’s time to retire the narrative of Medtronic as a perpetual laggard.

  83. ❖Jun 17, 1:08 PMnewsvia finnhub

    The Number That Could Test Johnson & Johnson Stock

    The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.

  84. ❖Jun 17, 11:20 AMnewsvia finnhub

    Worried About a Market Crash? These 3 Dividend Stocks Could Help Reduce Your Risk

    The stocks on this list offer above-average yields and aren't volatile investments.

  85. ❖Jun 17, 8:13 AMnewsvia finnhub

    Intuitive Surgical: Priced For Perfection, But The Growth Isn't Done

  86. ❖Jun 17, 2:25 AMnewsvia finnhub

    Needham Reiterates Buy on Medtronic, Maintains $101 Price Target

    Needham analyst Mike Matson reiterates Medtronic (NYSE:MDT) with a Buy and maintains $101 price target.

  87. ❖Jun 16, 10:21 AMnewsvia finnhub

    Is the Options Market Predicting a Spike in Medtronic Stock?

    Investors need to pay close attention to MDT stock based on the movements in the options market lately.

  88. ❖Jun 16, 6:35 AMnewsvia finnhub

    3 Dividend Stocks to Hold for the Long Haul

    They have a habit of consistently raising their payouts.

  89. ❖Jun 15, 3:25 PMnewsvia finnhub

    Truist Maintains Hold on Medtronic (MDT), Seeks Stronger EPS Growth

    Medtronic plc (NYSE:MDT) is included among the Top 10 Income Stocks with the Highest Upside Potential. On June 4, Truist reduced its price recommendation on Medtronic plc (NYSE:MDT) to $86 from $95. It reiterated a Hold rating on the shares. The firm pointed to a stronger-than-expected fourth quarter on the revenue side, with organic revenue […]

  90. ❖Jun 15, 7:49 AMnewsvia finnhub

    Is Zimmer Biomet Stock Underperforming the S&P 500?

    Zimmer Biomet has lagged the broader S&P 500 Index over the past year, and analysts remain on the sidelines as they weigh the company's steady fundamentals against its modest growth outlook.

  91. ❖Jun 15, 6:00 AMnewsvia finnhub

    Medtronic closes Scientia Vascular takeover, continuing M&A streak

    CEO Geoff Martha said the acquisition will enable “every neurovascular procedure to start with Medtronic.”

  92. ❖Jun 14, 4:06 PMnewsvia finnhub

    Medtronic Expands Neurovascular Reach With Scientia Deal As Stock Lags

    Medtronic (NYSE:MDT) has completed its acquisition of Scientia Vascular, a specialist in neurovascular guidewires and catheters. The deal expands Medtronic's neurovascular portfolio aimed at supporting physicians treating complex brain and vascular conditions. The move adds a fresh product set beyond Medtronic's recent pipeline and product approvals in a field with rising global demand. With the stock at $80.2, Medtronic is coming off a mixed run, with the share price down 16.5% year to...

  93. ❖Jun 14, 10:57 AMnewsvia finnhub

    Got $2,500? 1 Unstoppable Medical Juggernaut to Buy Hand Over Fist and Hold for the Next 20 Years

    For an investor in their 50s or 60s who is finished chasing trends, Medtronic (NYSE:MDT) is a stock worth owning for decades because it pairs inelastic demand for medical devices with a 49th consecutive year of dividend increases. A $2,500 stake at the current $80.33 share price buys roughly 31 shares of a business engineered ... Got $2,500? 1 Unstoppable Medical Juggernaut to Buy Hand Over Fist and Hold for the Next 20 Years

  94. ❖Jun 14, 7:15 AMnewsvia finnhub

    BofA Lowers PT on Medtronic (MDT) Stock

    Medtronic plc (NYSE:MDT) is one of the Best Bargain Stocks to Buy in June. On June 12, BofA reduced its price objective on the company’s stock to $95 from $110 and maintained a “Buy” rating on the shares. The firm’s services team has been highlighting a lower utilization environment, and thus, the analyst became more conservative […]

  95. ❖Jun 14, 1:36 AMnewsvia finnhub

    Analyst Lowers Medtronic (MDT) Price Target by $15. Here is Why

    With an annual dividend yield of 3.59%, Medtronic plc (NYSE:MDT) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. Medtronic plc (NYSE:MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. On June 5, Bernstein analyst Lee Hambright lowered the […]

  96. ❖Jun 12, 11:30 PMnewsvia finnhub

    Dividend Announcements: May 30-June 5, 2026

    Weekly dividend stock updates: 6 dividend increases plus a special dividend. Read here for a detailed analysis.

  97. ▣Jun 9, 8:00 PMjournalstop

    Agent 6 — Options Momentum closed long 100 @ $2.78 (-$98.13)

    Stop: premium $2.78 ≤ trailing floor $2.82 (peak $3.76 × 0.75)

  98. ✓Jun 4, 6:04 PMdecisionacted

    Agent 20 — SIR Price/Volume — buy

    [cluster_break_up] From 2026-05-07 through 2026-06-02, MDT traced a tight 20-day cluster between roughly $73.75 and $78.60 on unremarkable volume (ADV ~10–14M, largely consistent with the trailing 20-day mean of 11.5M), with the path drifting lower and consolidating near the $73.75–$75.98 band by late May. The cluster break began on 2026-06-03, when price surged +5.69% to $77.95 on 20.3M shares — a volume z-score implying well-above-average demand — and was immediately confirmed on 2026-06-04, where price extended another +5.11% to $81.93 on 19.4M shares (z-score 2.02), both sessions printing the two highest closes in the 20-day window. Under SIR's 2-D framework, two consecutive up-and-right dots escaping a well-defined lower-price cluster on materially expanding volume (nearly 2× the cluster-period ADV) constitute a textbook cluster_break_up with back-to-back session confirmation — the path, not just a single dot, supports the call. Risks: The break is only two sessions old; a failure to hold above the prior cluster ceiling (~$78.60, the 2026-05-22 high) on the next pullback — especially if that pullback arrives on expanding volume — would signal a false breakout and invalidate the read. Additionally, the flattening yield curve (T10Y2Y at 0.41, 2.1σ below trend as of 2026-06-03) creates a defensive-sector headwind that could suppress follow-through buying in Health Care names like MDT if macro sentiment deteriorates.

  99. ✓Jun 4, 6:03 PMdecisionacted

    Agent 6 — Options Momentum — decide: buy

    CALL on MDT — 5-day return 8.42% with close above 20-day MA ($76.81). IV 35.3%. Sized 1 contract(s) at $3.76 premium.

  100. ▢Jun 3, 8:00 PMjournal

    Agent 6 — Options Momentum opened long 100 @ $3.76

  101. ?Jun 3, 7:02 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device company with durable revenue streams, and the 15.2% drop does not appear linked to a confirmed fundamental impairment — no negative 8-K, guidance cut, or earnings miss visible in recent filings. However, the sector (XLV) is underperforming SPY meaningfully (-5.86pts over 30 days), suggesting the drop is at least partially sector-driven rather than purely idiosyncratic, which limits confidence in a near-term reversal. Options flow is modestly positive (P/C ratio 0.61, call z-score 1.25), but there are no insider cluster buys, no analyst upgrade signals, and no clear positive catalyst ahead of the August earnings date (77 days out, non-imminent but also non-supportive).

  102. !Jun 3, 7:02 AMsignalseverity 0.14

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device company with durable revenue streams, and the 15.2% drop does not appear linked to a confirmed fundamental impairment — no negative 8-K, guidance cut, or earnings miss visible in recent filings. However, the sector (XLV) is underperforming SPY meaningfully (-5.86pts over 30 days), suggesting the drop is at least partially sector-driven rather than purely idiosyncratic, which limits confidence in a near-term reversal. Options flow is modestly positive (P/C ratio 0.61, call z-score 1.25), but there are no insider cluster buys, no analyst upgrade signals, and no clear positive catalyst ahead of the August earnings date (77 days out, non-imminent but also non-supportive).

  103. ▣Jun 2, 8:00 PMjournalstop

    Agent 6 — Options Momentum closed long 300 @ $0.58 (-$450.66)

    Stop: premium $0.58 ≤ trailing floor $1.56 (peak $2.08 × 0.75)

  104. ?Jun 2, 6:04 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device company with durable revenue streams, and the 15.2% drop does not appear linked to a confirmed fundamental impairment — no negative 8-K, guidance cut, or earnings miss visible in recent filings. However, the sector (XLV) is underperforming SPY meaningfully (-5.86pts over 30 days), suggesting the drop is at least partially sector-driven rather than purely idiosyncratic, which limits confidence in a near-term reversal. Options flow is modestly positive (P/C ratio 0.61, call z-score 1.25), but there are no insider cluster buys, no analyst upgrade signals, and no clear positive catalyst ahead of the August earnings date (77 days out, non-imminent but also non-supportive).

  105. !Jun 2, 6:04 PMsignalseverity 0.14

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device company with durable revenue streams, and the 15.2% drop does not appear linked to a confirmed fundamental impairment — no negative 8-K, guidance cut, or earnings miss visible in recent filings. However, the sector (XLV) is underperforming SPY meaningfully (-5.86pts over 30 days), suggesting the drop is at least partially sector-driven rather than purely idiosyncratic, which limits confidence in a near-term reversal. Options flow is modestly positive (P/C ratio 0.61, call z-score 1.25), but there are no insider cluster buys, no analyst upgrade signals, and no clear positive catalyst ahead of the August earnings date (77 days out, non-imminent but also non-supportive).

  106. ?Jun 2, 6:04 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path traces a textbook distribution arc: MDT climbed from ~$74.54 (2026-05-11) to a closing peak of ~$78.60 (2026-05-22) predominantly on declining up-day volume (up days on 2026-05-14 saw only 7.4M, 2026-05-22 only 7.1M), while the subsequent breakdown has been accompanied by sharply expanding down-day volume — 10.5M on 2026-05-27, 13.1M on 2026-05-28, then a surge to 22.2M on 2026-05-29. Today's bar (2026-06-02, close $73.73, volume 24.3M, z-score +4.13) is the heaviest-volume session of the entire window and prints on a down day, reinforcing the distribution read rather than signaling a climax reversal — there is no preceding tight price cluster being broken to the upside, only a sustained step-down in price on accelerating sell-side volume. The path through 2-D space has drifted decisively down-and-right (higher volume, lower closes) since the May 22 peak, the defining SIR signature of institutional distribution. Risks: This bearish read would be invalidated if tomorrow's session produces a high-volume reversal close materially back above $75.57 (the 2026-05-28 close), suggesting today's volume spike was a selling climax rather than continued distribution. Additionally, a macro shift — such as a steepening yield curve reversing the current 2σ-below-trend T10Y2Y reading — could provide sector-level support that overwhelms the technical deterioration.

  107. ?Jun 2, 7:01 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device company with durable revenue streams, and the 15.2% drop does not appear linked to a confirmed fundamental impairment — no negative 8-K, guidance cut, or earnings miss visible in recent filings. However, the sector (XLV) is underperforming SPY meaningfully (-5.86pts over 30 days), suggesting the drop is at least partially sector-driven rather than purely idiosyncratic, which limits confidence in a near-term reversal. Options flow is modestly positive (P/C ratio 0.61, call z-score 1.25), but there are no insider cluster buys, no analyst upgrade signals, and no clear positive catalyst ahead of the August earnings date (77 days out, non-imminent but also non-supportive).

  108. !Jun 2, 7:01 AMsignalseverity 0.15

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device company with durable revenue streams, and the 15.2% drop does not appear linked to a confirmed fundamental impairment — no negative 8-K, guidance cut, or earnings miss visible in recent filings. However, the sector (XLV) is underperforming SPY meaningfully (-5.86pts over 30 days), suggesting the drop is at least partially sector-driven rather than purely idiosyncratic, which limits confidence in a near-term reversal. Options flow is modestly positive (P/C ratio 0.61, call z-score 1.25), but there are no insider cluster buys, no analyst upgrade signals, and no clear positive catalyst ahead of the August earnings date (77 days out, non-imminent but also non-supportive).

  109. ?Jun 1, 6:04 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device company with durable revenue streams, and the 15.2% drop does not appear linked to a confirmed fundamental impairment — no negative 8-K, guidance cut, or earnings miss visible in recent filings. However, the sector (XLV) is underperforming SPY meaningfully (-5.86pts over 30 days), suggesting the drop is at least partially sector-driven rather than purely idiosyncratic, which limits confidence in a near-term reversal. Options flow is modestly positive (P/C ratio 0.61, call z-score 1.25), but there are no insider cluster buys, no analyst upgrade signals, and no clear positive catalyst ahead of the August earnings date (77 days out, non-imminent but also non-supportive).

  110. !Jun 1, 6:04 PMsignalseverity 0.15

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device company with durable revenue streams, and the 15.2% drop does not appear linked to a confirmed fundamental impairment — no negative 8-K, guidance cut, or earnings miss visible in recent filings. However, the sector (XLV) is underperforming SPY meaningfully (-5.86pts over 30 days), suggesting the drop is at least partially sector-driven rather than purely idiosyncratic, which limits confidence in a near-term reversal. Options flow is modestly positive (P/C ratio 0.61, call z-score 1.25), but there are no insider cluster buys, no analyst upgrade signals, and no clear positive catalyst ahead of the August earnings date (77 days out, non-imminent but also non-supportive).

  111. ?Jun 1, 6:03 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  112. !Jun 1, 6:03 PMsignalseverity 0.15

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  113. ?Jun 1, 7:02 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device company with durable revenue streams, and the 15.2% drop does not appear linked to a confirmed fundamental impairment — no negative 8-K, guidance cut, or earnings miss visible in recent filings. However, the sector (XLV) is underperforming SPY meaningfully (-5.86pts over 30 days), suggesting the drop is at least partially sector-driven rather than purely idiosyncratic, which limits confidence in a near-term reversal. Options flow is modestly positive (P/C ratio 0.61, call z-score 1.25), but there are no insider cluster buys, no analyst upgrade signals, and no clear positive catalyst ahead of the August earnings date (77 days out, non-imminent but also non-supportive).

  114. !Jun 1, 7:02 AMsignalseverity 0.15

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device company with durable revenue streams, and the 15.2% drop does not appear linked to a confirmed fundamental impairment — no negative 8-K, guidance cut, or earnings miss visible in recent filings. However, the sector (XLV) is underperforming SPY meaningfully (-5.86pts over 30 days), suggesting the drop is at least partially sector-driven rather than purely idiosyncratic, which limits confidence in a near-term reversal. Options flow is modestly positive (P/C ratio 0.61, call z-score 1.25), but there are no insider cluster buys, no analyst upgrade signals, and no clear positive catalyst ahead of the August earnings date (77 days out, non-imminent but also non-supportive).

  115. ✓May 29, 6:03 PMdecisionacted

    Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

    Wanted to buy but only $9.19 cash available; close=$75.57.

  116. ✓May 29, 6:03 PMdecisionacted

    Agent 6 — Options Momentum — decide: buy

    PUT on MDT — 5-day return -5.54% with close below 20-day MA ($77.11). IV 23.6%. Sized 3 contract(s) at $2.08 premium.

  117. ?May 29, 7:01 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

    Wanted to buy but only $9.19 cash available; close=$75.57.

  118. !May 29, 7:01 AMsignal

    Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

    Wanted to buy but only $6.30 cash available; close=$75.98.

  119. ▢May 28, 8:00 PMjournal

    Agent 6 — Options Momentum opened long 300 @ $2.08

  120. ?May 28, 6:01 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  121. !May 28, 6:01 PMsignalseverity 0.14

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  122. ?May 28, 6:01 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

    Wanted to buy but only $6.30 cash available; close=$75.98.

  123. !May 28, 6:01 PMsignal

    Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

    Wanted to buy but only $8.03 cash available; close=$75.98.

  124. ?May 28, 7:01 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

    Wanted to buy but only $8.03 cash available; close=$75.98.

  125. !May 28, 7:01 AMsignal

    Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

    Wanted to buy but only $9.46 cash available; close=$77.60.

  126. ?May 27, 6:01 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  127. !May 27, 6:01 PMsignalseverity 0.12

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  128. ?May 27, 6:01 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

    Wanted to buy but only $9.46 cash available; close=$77.60.

  129. !May 27, 6:01 PMsignal

    Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

    Wanted to buy but only $21.36 cash available; close=$77.60.

  130. ?May 27, 7:01 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

    Wanted to buy but only $21.36 cash available; close=$77.60.

  131. !May 27, 7:01 AMsignal

    Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

    Wanted to buy but only $2.08 cash available; close=$78.60.

  132. ?May 26, 6:01 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  133. !May 26, 6:01 PMsignalseverity 0.11

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  134. ?May 26, 6:01 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

    Wanted to buy but only $2.08 cash available; close=$78.60.

  135. !May 26, 6:01 PMsignal

    Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

    Wanted to buy but only $0.00 cash available; close=$78.60.

  136. ?May 26, 7:02 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

    Wanted to buy but only $0.00 cash available; close=$78.60.

  137. !May 26, 7:02 AMsignal

    Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

    Medtronic is a large-cap, dividend-paying medical device leader (3.63% yield) with no confirmed fundamental impairment driving the 11.4% drop — the decline appears macro/sector-driven, as Health Care (XLV) has underperformed SPY by ~8pts over 30 days, suggesting the move is largely sector-wide rather than idiosyncratic. Options flow is nearly balanced (P/C ratio 0.93) with no unusual put loading, and today's sector flow proxy is notably positive (+$12M), suggesting near-term sector stabilization. No imminent earnings, no insider selling, and no negative SEC filings provide a relatively clean backdrop for a mean-reversion trade.

  138. ?May 22, 6:01 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  139. !May 22, 6:01 PMsignalseverity 0.12

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  140. ?May 22, 6:01 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  141. !May 22, 6:01 PMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  142. ?May 22, 7:01 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  143. !May 22, 7:01 AMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  144. ?May 21, 6:00 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  145. !May 21, 6:00 PMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  146. ?May 21, 6:00 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  147. !May 21, 6:00 PMsignalseverity 0.12

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  148. ?May 21, 11:47 AMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  149. !May 21, 11:47 AMsignalseverity 0.12

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  150. ?May 21, 11:46 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  151. !May 21, 11:46 AMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  152. ?May 21, 7:02 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  153. !May 21, 7:02 AMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  154. ?May 20, 6:01 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  155. !May 20, 6:01 PMsignalseverity 0.12

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  156. ?May 20, 6:01 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  157. !May 20, 6:01 PMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  158. ?May 20, 7:01 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  159. !May 20, 7:01 AMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  160. ?May 19, 6:02 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  161. !May 19, 6:02 PMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  162. ?May 19, 6:01 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  163. !May 19, 6:01 PMsignalseverity 0.13

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  164. ?May 19, 11:51 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MDT is up 1.68% today, a meaningful but not extreme intraday move. There are no recent headlines to explain the move, suggesting it may be driven by broader sector rotation or technical buying rather than a catalyst — which can sustain but also fade without reinforcement. The macro context shows 10-year inflation expectations (T10YIE) elevated at 2.4σ above trend, which is a headwind for long-duration sensitive sectors. MDT, as a large-cap medical device company, carries moderate duration sensitivity given its stable cash flows and valuation — this macro backdrop is a mild negative for continuation. However, with 235 minutes remaining, there is ample time for the move to extend if buying pressure persists. The move is not large enough to suggest exhaustion or a blow-off top. With no reversal signals evident and time still on the clock, the default lean is slight continuation, but the elevated inflation expectations cap conviction. Probability sits just above threshold.

  165. ?May 19, 9:28 AMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong balance sheet, and consistent dividends — fundamentally sound with no news or SEC filings in the window suggesting deterioration. The 13% drop from the 30-day high appears to be driven by macro headwinds rather than company-specific issues, most likely sector rotation away from long-duration, dividend-heavy healthcare names as the T10YIE is running 2.4σ above its 24-month trend, pressuring rate-sensitive equities. However, with elevated inflation expectations persisting and no near-term catalyst visible in the evidence, the path back to the 30-day high within 90 days faces a real macro headwind.

  166. ✓May 19, 7:04 AMdecisionacted

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    MDT (Medtronic) is a large-cap, diversified medical device company with no visible fundamental deterioration in the evidence window — no recent 10-Q/8-K flagging guidance cuts, covenant issues, or going-concern language. The 13% drop from the 30-day high appears to be predominantly sector-driven noise, as Health Care (XLV) is the weakest sector over 30 days at -12.48pts vs. SPY, suggesting the selloff is broad rather than idiosyncratic. Options flow shows a healthy call-skewed P/C ratio of 0.65, and there is no imminent earnings event to create binary risk, providing a clean 90-day runway.

  167. ?May 19, 7:02 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  168. ?May 18, 12:20 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Medtronic (MDT) is a large-cap, diversified medical device company with a long history of stable cash flows, a strong dividend track record, and a broad product portfolio across cardiac, diabetes, and surgical segments — all indicators of fundamental soundness. The absence of any recent negative headlines or SEC filings in the 30-day window suggests the 13.4% drop is more likely driven by macro rotation or broader market pressure rather than company-specific deterioration. However, the elevated 5-year inflation breakeven (T5YIE at 2.7, 2.5σ above trend) raises the cost of capital for dividend-heavy, slower-growth companies like MDT, which could dampen near-term multiple expansion and delay a rebound.

  169. ?May 18, 9:25 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap medical device leader (Medtronic) with a long track record of profitability, dividends, and diversified revenue — no confirmed fundamental impairment is visible in the evidence window. The 14.3% drop appears largely sector-driven, as Health Care (XLV) is the second-worst performer in 30-day relative strength (rank 10 of 11) and is down 13.87pts vs. SPY over 30 days, suggesting the dip is more macro/sector-wide than idiosyncratic. Options flow is mildly bullish with a P/C ratio of 0.85 (more calls than puts), but z-scores are unavailable so significance is unclear. However, negative sector flow proxy (-$13.8M today), broad market weakness (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE at 2.5σ above trend) create headwinds for a near-term mean reversion. No insider buying, no upcoming earnings catalyst, and no analyst upgrades are present to confirm a bottom.

  170. ?May 18, 9:00 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — analyze: fail

    Analyze call failed: No JSON object in analysis response: I'll work through the framework systematically. **STEP 1 — HARD VETO CHECK** - Earnings imminent: No earnings in visible window. No veto. - Fundamental deterioration: No 10-Q/8-K/8-K filings. No evid

  171. ?May 18, 8:54 AMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    MDT is a large-cap medical device leader with diversified revenue streams and a long dividend history, suggesting the underlying business remains structurally sound in the absence of any negative news or filings. The 14.3% drawdown from the 30-day high appears more consistent with macro-driven sector rotation or broad market pressure than company-specific deterioration. However, the elevated 5-year inflation breakeven (2.7%, 2.5σ above trend) creates a headwind for defensive, dividend-oriented healthcare names as real yields rise and discount rates compress valuations.

  172. ?May 16, 6:35 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

    Wanted to buy but only $6.08 cash available; close=$76.15.

  173. ?May 16, 10:05 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is down 14.3% from its 30-day high at $76.15, which on the surface appears to be a meaningful dip in a large-cap medical device name. However, the evidence base is almost entirely empty: no recent news headlines to explain the drop or suggest a catalyst for recovery, no SEC filings to assess fundamental health, no insider buying (which would be a meaningful positive signal for a value-oriented dip trade), and no options flow data to indicate informed positioning. Without understanding *why* the stock dropped 14.3%, buying into that move carries asymmetric downside risk — the decline could reflect deteriorating fundamentals, a product recall, reimbursement headwinds, or other sector-specific issues not yet visible in this data window. The broader market is risk-off today (SPY -1.20%, IWM -2.41%), adding near-term headwind. The macro backdrop is modestly cautious: 10Y at 4.47% is near the structural headwind threshold, 5Y inflation breakevens are running 2.5σ above trend (a negative for rate-sensitive health care equipment companies with large debt loads like MDT), and VIX at the 50th percentile is neutral but not supportive of aggressive dip-buying. The 2s10s spread is mildly positive (+0.47pp), which is not alarming but not a tailwind. Sector context is unavailable, so it is impossible to determine whether this is idiosyncratic weakness or a sector-wide move. With no confirming signals across any evidence category — no insider buying, no bullish options flow, no fundamental catalyst, no sector support — the conservative posture is to pass.

  174. ?May 16, 9:19 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MDT has dropped 14.3% from its 30-day high to $76.15, which is a meaningful dislocation for a large-cap medtech name. However, the evidence base is critically thin: no recent news headlines, no SEC filings, no insider activity, and no options flow data are available to explain or contextualize the decline. Without knowing the catalyst for the drop, it is impossible to assess whether the selloff is overdone or reflects a legitimate deterioration in fundamentals (e.g., guidance cut, product recall, reimbursement headwind). The absence of any cluster insider buying removes what would be a strong positive signal at this price level. The macro backdrop is mildly unfavorable: the 10Y at 4.47% is approaching the structural headwind threshold for a dividend-paying, FCF-valued healthcare name like MDT, and 5Y inflation breakevens printing 2.7 (2.5σ above trend) suggest cost-of-capital pressure may persist. Broad market tone today is risk-off (SPY -1.2%, IWM -2.4%), which adds near-term technical headwinds. VIX at the 50th percentile is neutral — not alarming, but not a green light either. The 2s10s spread is mildly positive, removing one bear signal. Overall, with no confirmatory evidence supporting a mean-reversion thesis and an unexplained catalyst driving the decline, the risk/reward does not clear the bar for a 90-day swing trade.

  175. ?May 16, 9:01 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MDT is a large-cap medical device leader with durable cash flows and a long dividend history, suggesting the underlying business remains financially sound in the absence of any disclosed deterioration via filings or headlines. However, the 13.4% drop from the 30-day high while broad markets are rallying strongly today (SPY +0.79%, QQQ +0.71%, VXX -2.54%) signals idiosyncratic stress rather than macro contagion — a meaningful red flag given no explanatory news is available to contextualize the selloff. Elevated inflation expectations (T5YIE at 2.5σ above trend) could compress valuations for slow-growth healthcare names, and without fresh catalysts or filings to confirm the thesis, conviction in a 90-day rebound to prior highs is limited.

  176. ?May 16, 9:00 AMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    MDT is a large-cap medical device leader with diversified revenue streams and a long dividend history, suggesting the underlying business remains structurally sound in the absence of any negative news or filings. The 14.3% drawdown from the 30-day high appears more consistent with macro-driven sector rotation or broad market pressure than company-specific deterioration. However, the elevated 5-year inflation breakeven (2.7%, 2.5σ above trend) creates a headwind for defensive, dividend-oriented healthcare names as real yields rise and discount rates compress valuations.

  177. ?May 16, 8:58 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap, diversified medical device company with durable franchises and historically stable cash flows, suggesting the underlying business remains financially sound in the absence of any disqualifying news or SEC filings indicating deterioration. However, the 13.4% decline from the 30-day high is notable and appears idiosyncratic — broad market indices (SPY +0.79%, QQQ +0.71%, DIA +0.74%) are all positive today, meaning this drop is not explained by macro contagion but rather by company-specific or sector-specific stress that is unidentified due to the absence of news headlines. The elevated 5-year inflation breakeven (T5YIE at 2.7, 2.5σ above trend) is a modest headwind for rate-sensitive defensive healthcare names with significant debt, limiting near-term multiple expansion.

  178. ?May 15, 6:37 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MDT is a large-cap, diversified medical device company with durable franchises and historically stable cash flows, suggesting the underlying business remains financially sound in the absence of any disqualifying news or SEC filings indicating deterioration. However, the 13.4% decline from the 30-day high is notable and appears idiosyncratic — broad market indices (SPY +0.79%, QQQ +0.71%, DIA +0.74%) are all positive today, meaning this drop is not explained by macro contagion but rather by company-specific or sector-specific stress that is unidentified due to the absence of news headlines. The elevated 5-year inflation breakeven (T5YIE at 2.7, 2.5σ above trend) is a modest headwind for rate-sensitive defensive healthcare names with significant debt, limiting near-term multiple expansion.

← Back to dashboard